Content by Keyword: Intellectual Property

  • Home
  • Intellectual Property
  • print
  • email
  • twitter
  • compact
Report
Performance Improvement 2011-2012

Performance Improvement 2011-2012

This report, Performance Improvement 2011-2012, the 17th in this series, summarizes the key findings from studies completed during the two fiscal-year period ending September 30, 2011.
  • PerformanceImprovement2011-2012.pdf
    export-csvPDF
Report page
Appendix E - Studies by Agency

Performance Improvement 2009. Appendix E - Studies by Agency

Studies by Agency Elements of evaluation: Effective programs achieve results. Results derive from good management which requires good decisions. Good decision-making depends on good information. Good information requires good data and careful analysis. Creative project officers, skillful researchers, thoughtful an
Report page
Can the National Institutes for Health and the

Performance Improvement 2009. Can the National Institutes for Health and the Food and Drug Administration Integrate their Intellectual Property Portfolios?

The National Institutes of Health (NIH) Office of Technology Transfer, evaluates, protects, markets, licenses, monitors, and manages NIH and Food and Drug Administration (FDA) invention portfolios. The large number of inventions and their interdisciplinary nature make extracting and evaluating this information difficult. A proof-of-concept system
Report page
Research

Performance Improvement 1999. Research

TITLE: Defining a Comprehensive School Health Program: An Interim Statement
Report page
Evaluation of the International Cooperative

Performance Improvement 1999. Evaluation of the International Cooperative Biodiversity Groups

Highlights The International Cooperative Biodiversity Groups (ICBG) are the first large scale, multi-country attempt to combine natural products drug discovery with measures to promote conservation of diverse biological species around the world. This study evaluated the ICBGs to determine their progress in achieving their goals and o
Report page
National Institute of Health

Performance Improvement 1998. National Institute of Health

Contents The Status of Biomedical Research Facilities 1996 Evaluation of the National Research Service Award Research Training Programs National Heart, Lung, and Blood Institute Article Citation and Patent Reference Study: An Analysis of Article Citations and Patent References to Journal Articles Supported by the N
Report page
Agency for Health Care Policy and Research

Performance Improvement 1998. Agency for Health Care Policy and Research

Contents Publications of the Patient Outcomes Research Teams (PORTS), May 1996 and Medical Treatment Effectiveness Projects 1989 through 1995 Final Report on Changes Needed in CONQUEST's Software Based Programs Final Report on Changes Needed in CONQUEST 1.0's Structure and Classification Scheme Assessment of the
Report
Performance Improvement 1998

Performance Improvement 1998

Performance Improvement 1998 is the third annual report of the U.S. Department of Health and Human Services (HHS) on its evaluation activities. As a report to Congress, it summarizes the findings of HHS evaluations completed in fiscal year (FY) 1997. In that year, HHS agencies produced 155 evaluation reports and supported more than 335 evaluation
Report
Performance Improvement 2013-2014

Performance Improvement 2013-2014

This report, Performance Improvement 2013-2014, the 18th in this series, summarizes the key findings from studies completed during the two fiscal-year period ending September 30, 2013.
  • PerformanceImprovement2014.pdf
    export-csvPDF
Report
The Feasibility of Using Electronic Health Data

The Feasibility of Using Electronic Health Data for Research on Small Populations

Background. Many small populations have distinctive health and health care needs but have been difficult to study in survey research. Objective. This report is part of a project funded by the Assistant Secretary for Planning and Evaluation to explore the feasibility of using electronic health record (EHR) and other electronic health data for resea
  • rpt_ehealthdata.pdf
    export-csvPDF
Report
Examination of Clinical Trial Costs and Barriers

Examination of Clinical Trial Costs and Barriers for Drug Development

Pharmaceutical companies conduct clinical trials for many reasons. The most obvious goal of clinical trials is to demonstrate safety and efficacy to gain Food and Drug Administration (FDA) approval. FDA provides guidance to developers about what constitutes acceptable clinical trials and appropriate outcomes. Improving the drug development process
  • rpt_erg.pdf
    export-csvPDF
Report
Analytical Framework for Examining the Value of

Analytical Framework for Examining the Value of Antibacterial Products

Antibacterial resistance is a growing global problem.  At least 2 million people in the U.S. acquire serious infections with bacteria that are resistant to one or more of antibacterial drugs designed to treat it.  Despite the potential of new antibacterial products to reduce the social burden associated with resistant infections, development of
  • rpt_antibacterials.pdf
    export-csvPDF
Report
Performance Improvement 2009 and program

Performance Improvement 2009

This report fulfills a statutory obligation of the Department of Health and Human Services. Section 241 of the Public Health Service Act directs the Secretary to inform Congress annually concerning findings from evaluations conducted by the Department. As required, the report is submitted to the Senate Health, Education, Labor and Pensions Committ
  • PerformanceImprovement2009.pdf
    export-csvPDF
Report
Performance Improvement 1999

Performance Improvement 1999

Performance Improvement 1999: Evaluation Activities of the U.S. Department of Health and Human Services is the fifth annual report to Congress summarizing previous fiscal year evaluation efforts. The purpose of this report is to provide Congress with evaluative information on the Department's programs, policies, activities, and strategies. It cont

Pages